Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

CDKN1C/p57kip2is a candidate tumor suppressor gene in human breast cancer

Authors: Pamela S Larson, Benjamin L Schlechter, Chia-Lin King, Qiong Yang, Chelsea N Glass, Charline Mack, Robert Pistey, Antonio de las Morenas, Carol L Rosenberg

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

CDKN1C (also known as p57KIP2) is a cyclin-dependent kinase inhibitor previously implicated in several types of human cancer. Its family members (CDKN1A/p21CIP1 and B/p27KIP1) have been implicated in breast cancer, but information about CDKN1C's role is limited. We hypothesized that decreased CDKN1C may be involved in human breast carcinogenesis in vivo.

Methods

We determined rates of allele imbalance or loss of heterozygosity (AI/LOH) in CDKN1C, using an intronic polymorphism, and in the surrounding 11p15.5 region in 82 breast cancers. We examined the CDKN1C mRNA level in 10 cancers using quantitative real-time PCR (qPCR), and the CDKN1C protein level in 20 cancers using immunohistochemistry (IHC). All samples were obtained using laser microdissection. Data were analyzed using standard statistical tests.

Results

AI/LOH at 11p15.5 occurred in 28/73 (38%) informative cancers, but CDKN1C itself underwent AI/LOH in only 3/16 (19%) cancers (p = ns). In contrast, CDKN1C mRNA levels were reduced in 9/10 (90%) cancers (p < 0.0001), ranging from 2–60% of paired normal epithelium. Similarly, CDKN1C protein staining was seen in 19/20 (95%) cases' normal epithelium but in only 7/14 (50%) cases' CIS (p < 0.004) and 5/18 (28%) cases' IC (p < 0.00003). The reduction appears primarily due to loss of CDKN1C expression from myoepithelial layer cells, which stained intensely in 17/20 (85%) normal lobules, but in 0/14 (0%) CIS (p < 0.00001). In contrast, luminal cells displayed less intense, focal staining fairly consistently across histologies. Decreased CDKN1C was not clearly associated with tumor grade, histology, ER, PR or HER2 status.

Conclusion

CDKN1C is expressed in normal epithelium of most breast cancer cases, mainly in the myothepithelial layer. This expression decreases, at both the mRNA and protein level, in the large majority of breast cancers, and does not appear to be mediated by AI/LOH at the gene. Thus, CDKN1C may be a breast cancer tumor suppressor.
Appendix
Available only for authorised users
Literature
1.
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75 (4): 805-816. 10.1016/0092-8674(93)90499-G.CrossRefPubMed
2.
Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994, 78 (1): 67-74. 10.1016/0092-8674(94)90573-8.CrossRefPubMed
3.
Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994, 78 (1): 59-66. 10.1016/0092-8674(94)90572-X.CrossRefPubMed
4.
Lee M-H, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Development. 1995, 9: 639-649. 10.1101/gad.9.6.639.CrossRef
5.
Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1Cdk inhibitor family, is a candidate tumor suppressor gene. Genes & Development. 1995, 9: 650-662. 10.1101/gad.9.6.650.CrossRef
6.
De Clercq A, Inze D: Cyclin-dependent kinase inhibitors in yeast, animals, and plants: a functional comparison. Critical reviews in biochemistry and molecular biology. 2006, 41 (5): 293-313. 10.1080/10409230600856685.CrossRefPubMed
7.
Matsuoka S, Thompson JS, Edwards MC, Barletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg AP: Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA. 1996, 93: 3026-3030. 10.1073/pnas.93.7.3026.CrossRefPubMedPubMedCentral
8.
Liu J, Kahri AI, Heikkila P, Voutilainen R: Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19 in adrenal tumors and cultured adrenal cells. Journal of Clinical Endocrinology and Metabolism. 1997, 82 (6): 1766-1771. 10.1210/jc.82.6.1766.PubMed
9.
Bourcigaux N, Gaston V, Logic A, Bertagna X, Le Bouc Y, Gicquel C: High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2000, 85: 322-330. 10.1210/jc.85.1.322.PubMed
10.
Fan GK, Chen J, Ping F, Geng Y: Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral oncology. 2006, 42 (2): 147-153. 10.1016/j.oraloncology.2005.06.017.CrossRefPubMed
11.
Fan GK, Xu F, Yang B, Fujieda S: p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta oto-laryngologica. 2006, 126 (3): 301-305.CrossRefPubMed
12.
Bonilla F, Orlow I, Cordon-Cardo C: Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hetaptocellular carcinoma. Int J Oncol. 1998, 12 (3): 583-588.PubMed
13.
Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M, Matsuura N: Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology. 2001, 61 (3): 221-225. 10.1159/000055378.CrossRefPubMed
14.
Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N: Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas. 2001, 23 (3): 246-250. 10.1097/00006676-200110000-00004.CrossRefPubMed
15.
Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M: Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res. 2005, 11 (13): 4681-4688. 10.1158/1078-0432.CCR-04-2471.CrossRefPubMed
16.
Oya M, Schulz WA: Decreased expression of p57(KIP2)mRNA in human bladder cancer. British journal of cancer. 2000, 83 (5): 626-631. 10.1054/bjoc.2000.1298.CrossRefPubMedPubMedCentral
17.
Hoffmann MJ, Florl AR, Seifert HH, Schulz WA: Multiple mechanisms downregulate CDKN1C in human bladder cancer. International journal of cancer. 2005, 114 (3): 406-413. 10.1002/ijc.20749.CrossRefPubMed
18.
Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, Ouchida M, Aoe M, Date H, et al: Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncology reports. 2004, 12 (5): 1087-1092.PubMed
19.
Kondo M, Matsuoka S, Uchida K, Osada H, Nagatake M, Takagi K, Harper JW, Takahashi T, Elledge SJ, Takahashi T: Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene. 1996, 12 (6): 1365-1368.PubMed
20.
Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, Nikolaidis G, Sigala F, Kittas C, Field JK, et al: Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. International journal of cancer. 2006, 119 (11): 2546-2556. 10.1002/ijc.22214.CrossRefPubMed
21.
Chilosi M, Piazzola E, Lestani M, Benedetti A, Guasparri I, Granchelli G, Aldovini D, Leonardi E, Pizzolo G, Doglioni C, et al: Differential expression of p57KIP2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Laboratory Investigation. 1998, 78: 269-276.PubMed
22.
Thompson JS, Reese KJ, DeBaun MR, Perlman EJ, Feinberg AP: Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor. Cancer Research. 1996, 56: 5723-5727.PubMed
23.
Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, et al: An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nature genetics. 1996, 14 (2): 171-173. 10.1038/ng1096-171.CrossRefPubMed
24.
Samuelsson MK, Pazirandeh A, Davani B, Okret S: p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Molecular endocrinology (Baltimore, Md). 1999, 13 (11): 1811-1822. 10.1210/me.13.11.1811.CrossRef
25.
Joaquin M, Watson RJ: The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain. The Journal of biological chemistry. 2003, 278 (45): 44255-44264. 10.1074/jbc.M308953200.CrossRefPubMed
26.
Scandura JM, Boccuni P, Massague J, Nimer SD: Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proceedings of the National Academy of Sciences of the United States of America. 2004, 101 (42): 15231-15236. 10.1073/pnas.0406771101.CrossRefPubMedPubMedCentral
27.
Nijjar T, Wigington D, Garbe JC, Waha A, Stampfer MR, Yaswen P: p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res. 1999, 59: 5112-5118.PubMed
28.
Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, Kimber I, Orphanides G: Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. Journal of molecular endocrinology. 2005, 34 (2): 535-551. 10.1677/jme.1.01677.CrossRefPubMed
29.
Chisholm K, Bray BJ, Rosengren RJ: Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anti-cancer drugs. 2004, 15 (9): 889-897. 10.1097/00001813-200410000-00010.CrossRefPubMed
30.
Hsu S, Lewis JB, Borke JL, Singh B, Dickinson DP, Caughman GB, Athar M, Drake L, Aiken AC, Huynh CT, et al: Chemopreventive effects of green tea polyphenols correlate with reversible induction of p57 expression. Anticancer research. 2001, 21: 3743-3748.PubMed
31.
Ravindranath MH, Saravanan TS, Monteclaro CC, Presser N, Ye X, Selvan SR, Brosman S: Epicatechins Purified from Green Tea (Camellia sinensis) Differentially Suppress Growth of Gender-Dependent Human Cancer Cell Lines. Evid Based Complement Alternat Med. 2006, 3 (2): 237-247. 10.1093/ecam/nel003.CrossRefPubMedPubMedCentral
32.
Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J, Guillen JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anti-cancer drugs. 1996, 7 (4): 461-468. 10.1097/00001813-199606000-00011.CrossRefPubMed
33.
Gudmundsson J, Barkardottir RB, Eiriksdottir G, Baldursson T, Arason A, Egilsson V, Ingvarsson S: Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British journal of cancer. 1995, 72 (3): 696-701.CrossRefPubMedPubMedCentral
34.
Karnik P, Paris M, Williams BRG, Casey G, Crowe J, Chen P: Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastatsis. Human Molecular Genetics. 1998, 7: 895-903. 10.1093/hmg/7.5.895.CrossRefPubMed
35.
Lichy JH, Zavar M, Tsai MM, O'Leary TJ, Taubenberger JK: Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. The American journal of pathology. 1998, 153 (1): 271-278.CrossRefPubMedPubMedCentral
36.
Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, Nakamura Y: Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Human Genetics. 1996, 97: 625-631. 10.1007/BF02281873.CrossRefPubMed
37.
38.
Schlechter BL, Yang Q, Larson PS, Golubeva A, Blanchard RA, de las Morenas A, Rosenberg CL: Quantitative DNA fingerprinting may distinguish new primary breast cancer from disease recurrence. J Clin Oncol. 2004, 22 (10): 1830-1838. 10.1200/JCO.2004.05.123.CrossRefPubMed
39.
Larson P, de Las Morenas A, Cerda S, Bennett S, Cupples L, Rosenberg C: Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. J Pathol. 2006
40.
Larson PS, Ungarelli RA, de Las Morenas A, Cupples LA, Rowlings K, Palmer JR, Rosenberg CL: In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium. Cancer. 2006, 107 (9): 2122-2126. 10.1002/cncr.22223.CrossRefPubMed
41.
Rosenberg CL, Finnemore EM, Larson PS, Nogueira CP, Delaney TL: DNA alterations in tumor scrapes vs. biopsies of squamous-cell carcinomas of the head and neck. Int J Cancer. 2000, 89 (2): 105-110. 10.1002/(SICI)1097-0215(20000320)89:2<105::AID-IJC1>3.0.CO;2-O.CrossRefPubMed
42.
King C, Guo N, Frampton GM, Gerry NP, Lenburg ME, Rosenberg CL: Reliability and reproducibility of gene expression measurements using amplified RNA from laser-microdissected primary breast tissue with oligonucleotide arrays. J Mol Diagn. 2005, 7 (1): 57-64.CrossRefPubMedPubMedCentral
43.
Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M, Bustin SA, Orlando C: Quantitative real-time reverse transcription polymerase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem. 2002, 309 (2): 293-300. 10.1016/S0003-2697(02)00311-1.CrossRefPubMed
44.
Kerangueven F, Noguchi T, Coulier F, Allione F, Wargniez V, Simony-Lafontaine J, Longy M, Jacquemier J, Sobol H, Eisinger F, et al: Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res. 1997, 57 (24): 5469-5474.PubMed
45.
Osborne RJ, Hamshere MG: A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res. 2000, 60 (14): 3706-3712.PubMed
46.
Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW: Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 2000, 60 (14): 3884-3892.PubMed
47.
Editors, Lakhani S, Bissell M: The role of myoepithelial cells in integration of form and function in the mammary gland. Journal of mammary gland biology and neoplasia. 2005, 10 (3): 197-280. 10.1007/s10911-005-9580-x.
48.
Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, et al: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004, 64 (9): 3037-3045. 10.1158/0008-5472.CAN-03-2028.CrossRefPubMed
49.
Figliola R, Maione R: MyoD induces the expression of p57Kip2 in cells lacking p21Cip1/Waf1: overlapping and distinct functions of the two cdk inhibitors. Journal of cellular physiology. 2004, 200 (3): 468-475. 10.1002/jcp.20044.CrossRefPubMed
Metadata
Title
CDKN1C/p57kip2is a candidate tumor suppressor gene in human breast cancer
Authors
Pamela S Larson
Benjamin L Schlechter
Chia-Lin King
Qiong Yang
Chelsea N Glass
Charline Mack
Robert Pistey
Antonio de las Morenas
Carol L Rosenberg
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-68

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Recurrent and multiple bladder tumors show conserved expression profiles

Research article

Quantum dots in axillary lymph node mapping: Biodistribution study in healthy mice

Study protocol

Biomonitoring of complex occupational exposures to carcinogens: The case of sewage workers in Paris

Research article

Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12myotubes

Research article

Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer

Research article

Association of common ATMvariants with familial breast cancer in a South American population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits